S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
NASDAQ:AEZS

Aeterna Zentaris (AEZS) Stock Forecast, Price & News

$2.47
-0.02 (-0.80%)
(As of 09/26/2023 ET)
Compare
Today's Range
$2.44
▼
$2.48
50-Day Range
$2.44
▼
$3.19
52-Week Range
$2.32
▼
$4.40
Volume
6,753 shs
Average Volume
12,081 shs
Market Capitalization
$11.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Aeterna Zentaris MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,033.6% Upside
$28.00 Price Target
Short Interest
Healthy
1.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Aeterna Zentaris in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.67) to ($3.15) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

850th out of 964 stocks

Pharmaceutical Preparations Industry

389th out of 438 stocks

See Top Rated MarketRank™ Stocks Here

AEZS stock logo

About Aeterna Zentaris (NASDAQ:AEZS) Stock

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

AEZS Price History

AEZS Stock News Headlines

September 27, 2023 | americanbankingnews.com
Aeterna Zentaris (NASDAQ:AEZS) Earns Sell Rating from Analysts at StockNews.com
September 27, 2023 | americanbankingnews.com
Comparing Aeterna Zentaris (NASDAQ:AEZS) & Entrada Therapeutics (NASDAQ:TRDA)
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 19, 2023 | americanbankingnews.com
Aeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at StockNews.com
September 12, 2023 | theglobeandmail.com
Closing Bell: Aeterna Zentaris Inc down on Monday (AEZS)
September 5, 2023 | finance.yahoo.com
Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 15, 2023 | theglobeandmail.com
Closing Bell: Aeterna Zentaris Inc flat on Tuesday (AEZS)
August 10, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Aeterna Zentaris (AEZS)
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
August 9, 2023 | finance.yahoo.com
Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates
July 13, 2023 | finance.yahoo.com
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
June 15, 2023 | finanznachrichten.de
Aeterna Zentaris Inc: Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders
May 26, 2023 | theglobeandmail.com
Closing Bell: Aeterna Zentaris Inc down on Friday (AEZS)
May 17, 2023 | theglobeandmail.com
Closing Bell: Aeterna Zentaris Inc down on Tuesday (AEZS)
May 15, 2023 | finance.yahoo.com
Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders
May 12, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Aeterna Zentaris (AEZS)
May 10, 2023 | finanznachrichten.de
Aeterna Zentaris Inc: Aeterna Zentaris Reports First Quarter 2023 Financial Results
May 9, 2023 | finance.yahoo.com
Aeterna Zentaris Reports First Quarter 2023 Financial Results
April 27, 2023 | theglobeandmail.com
Closing Bell: Aeterna Zentaris Inc down on Wednesday (AEZS)
April 6, 2023 | theglobeandmail.com
Closing Bell: Aeterna Zentaris Inc up on Thursday (AEZS)
April 6, 2023 | theglobeandmail.com
Closing Bell: Aeterna Zentaris Inc up on Wednesday (AEZS)
April 6, 2023 | finance.yahoo.com
Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug
April 5, 2023 | finanznachrichten.de
Aeterna Zentaris Inc: Aeterna Zentaris Provides Update on Macrilen (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
April 5, 2023 | finance.yahoo.com
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
March 23, 2023 | finance.yahoo.com
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
March 23, 2023 | financialpost.com
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
March 16, 2023 | finance.yahoo.com
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)
See More Headlines
Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

AEZS Company Calendar

Last Earnings
8/09/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AEZS
CUSIP
N/A
CIK
1113423
Web
www.zentaris.com
Phone
(418) 652-8525
Fax
418-948-9191
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.00
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+1,033.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-22,730,000.00
Net Margins
-259.71%
Pretax Margin
-259.71%
Return on Equity
-39.30%
Return on Assets
-25.94%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.26
Quick Ratio
11.23

Sales & Book Value

Annual Sales
$8.72 million
Price / Sales
1.38
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.37 per share
Price / Book
0.34

Miscellaneous

Outstanding Shares
4,856,000
Free Float
4,851,000
Market Cap
$11.99 million
Optionable
Optionable
Beta
1.35

Social Links

10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Klaus Paulini Ph.D.
    Pres, CEO & Exec. Director
  • Mr. Giuliano La Fratta
    Sr. VP of Fin. & CFO
  • Dr. Michael Teifel Ph.D.
    Sr. VP of Non-Clinical Devel. & Chief Scientific Officer
  • Dr. Nicola Ammer M.D.
    Chief Medical Officer & Sr. VP of Clinical Devel.
  • Dr. Matthias Gerlach
    Sr. VP Manufacturing & Supply Chain

Key Competitors

View All Competitors













AEZS Stock - Frequently Asked Questions

Should I buy or sell Aeterna Zentaris stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AEZS shares.
View AEZS analyst ratings or view top-rated stocks.

What is Aeterna Zentaris' stock price forecast for 2023?

1 equities research analysts have issued 12-month target prices for Aeterna Zentaris' stock. Their AEZS share price forecasts range from $28.00 to $28.00. On average, they expect the company's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 1,033.6% from the stock's current price.
View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts.

How have AEZS shares performed in 2023?

Aeterna Zentaris' stock was trading at $3.18 at the beginning of the year. Since then, AEZS shares have decreased by 22.3% and is now trading at $2.47.
View the best growth stocks for 2023 here.

When is Aeterna Zentaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AEZS earnings forecast.

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) issued its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.35. The biopharmaceutical company had revenue of $2.25 million for the quarter, compared to analyst estimates of $1.10 million. Aeterna Zentaris had a negative net margin of 259.71% and a negative trailing twelve-month return on equity of 39.30%.

When did Aeterna Zentaris' stock split?

Aeterna Zentaris shares reverse split on Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Aeterna Zentaris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG).

What is Aeterna Zentaris' stock symbol?

Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

How do I buy shares of Aeterna Zentaris?

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $2.47.

How much money does Aeterna Zentaris make?

Aeterna Zentaris (NASDAQ:AEZS) has a market capitalization of $11.99 million and generates $8.72 million in revenue each year. The biopharmaceutical company earns $-22,730,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis.

How can I contact Aeterna Zentaris?

Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The official website for the company is www.zentaris.com. The biopharmaceutical company can be reached via phone at (418) 652-8525, via email at ir@aezsinc.com, or via fax at 418-948-9191.

This page (NASDAQ:AEZS) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -